1-3 of 3
Jitka Osickova
Close
Sort by
Journal Articles

Rituximab Preferentially Eliminates BCR Signaling Proficient Chronic Lymphocytic Leukemia B Cells In Vivo

Gabriela Pavlasova, Marek Borsky, Katerina Musilova, Vaclav Seda, Katerina Cerna, Jitka Osickova, Eva Vojackova, Yvona Brychtova, Michael Doubek, Sarka Pospisilova, Jiri Mayer, Marek Mraz
Journal: Blood
Blood (2016) 128 (22): 2030.
https://doi.org/10.1182/blood.V128.22.2030.2030
Published: 2016
Journal Articles

Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis

Brief Report
Gabriela Pavlasova, Marek Borsky, Vaclav Seda, Katerina Cerna, Jitka Osickova, Michael Doubek, Jiri Mayer, Raffaele Calogero, Martin Trbusek, Sarka Pospisilova, Matthew S. Davids, Thomas J. Kipps, Jennifer R. Brown, Marek Mraz
Journal: Blood
Blood (2016) 128 (12): 1609–1613.
https://doi.org/10.1182/blood-2016-04-709519
Published: 2016
Includes: Supplemental data
Journal Articles

Microenvironmental Interactions up-Regulate CD20 Expression in CLL B Cells through the CXCR4/SDF-1 Axis: Implications for CD20-Targeting Antibodies and the Use of BCR-Inhibitors in Combination

Gabriela Pavlasova, MSc, Vaclav Seda, MSc, Marek Borsky, MSc., Katerina Cerna, MSc, Jitka Osickova, PhD, Jiri Mayer, Prof., MD, Sarka Pospisilova, Matthew S. Davids, MD, Jennifer R. Brown, MD PhD, Marek Mraz, MD PhD
Journal: Blood
Blood (2015) 126 (23): 4124.
https://doi.org/10.1182/blood.V126.23.4124.4124
Published: 2015